SPOTLIGHT: Wyeth may cut 10% of jobs

Welcome Wyeth to the layoff parade. The drug maker is plotting cutbacks, including job cuts that could amount to 10 percent of its 50,000-person workforce. Report

Suggested Articles

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .

OrbiMed, Novartis Venture Fund and RA Capital Management have joined forces to fund and help launch GentiBio.

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.